Massimo Boemi

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients

Antonio Ceriello, Katherine Esposito, Ludovica Piconi et al. · Diabetes · 2008 · 1.3K citations · Full text

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Olga Vaccaro, Maria Masulli, Antonio Nicolucci et al. · The Lancet Diabetes & Endocrinology · 2017 · 285 citations

Diabetes Management, Cardiovascular Disease, Diabetes +9

Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation

Massimo Boemi, Ilia Leviev, C. Sirolla et al. · Atherosclerosis · 2001 · 129 citations

Type 1, Biochemistry, Serum Paraoxonase +9

MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications

Olivieri Fabiola, Liana Spazzafumo, Massimiliano Bonafè et al. · Oncotarget · 2015 · 127 citations · Full text